| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Tubulis GmbH | <1 mi |
| Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | Phase 1/2 | MBrace Therapeutics | <1 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | <1 mi |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Phase 2 | BioNTech SE | <1 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | <1 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | <1 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | <1 mi |
| CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Phase 1 | University of Texas Southwestern Medical Center | <1 mi |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Phase 1 | Normunity AccelCo, Inc. | <1 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | <1 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | <1 mi |
| Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | Phase 1/2 | Hummingbird Bioscience | <1 mi |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | <1 mi |
| Study of XB010 in Subjects With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Phase 1 | GlaxoSmithKline | <1 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | Pliant Therapeutics, Inc. | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | <1 mi |
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer | Phase 1 | Boundless Bio, Inc. | <1 mi |
| Cancer Pain Management Using a Web-based Intervention | N/A | University of Texas at Austin | <1 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | Phase 1 | Cogent Biosciences, Inc. | <1 mi |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | — | Adela, Inc | <1 mi |
| Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase 1 | Zumutor Biologics Inc. | <1 mi |
| A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Phase 1/2 | Terremoto Biosciences Inc. | <1 mi |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab | Phase 1 | AbbVie | <1 mi |
| Sample Collection for Ongoing Research and Product Evaluation Study | — | Natera, Inc. | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery | Phase 1 | SURGE Therapeutics | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1 | Accent Therapeutics | <1 mi |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Phase 1 | Biotheryx, Inc. | <1 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | <1 mi |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| SLV-154 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | <1 mi |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Phase 1/2 | Eikon Therapeutics | <1 mi |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase 1/2 | Phoenix Molecular Designs | <1 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Phase 1/2 | Ensem Therapeutics | <1 mi |
| PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | Phase 1 | ProteinQure Inc. | <1 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | <1 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | <1 mi |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Phase 1 | Circle Pharma | <1 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| IDOV-Immune for Advanced Solid Tumors | Phase 1 | ViroMissile, Inc. | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors | Phase 1 | EMD Serono Research & Development Institute, Inc. | <1 mi |
| Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials | N/A | Eastern Cooperative Oncology Group | <1 mi |
| Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy | Phase 1 | The University of Texas Health Science Center at San Antonio | <1 mi |
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | <1 mi |
| Study of LP-184 in Patients With Advanced Solid Tumors | Phase 1/2 | Lantern Pharma Inc. | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer | Phase 1 | Genentech, Inc. | <1 mi |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | <1 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Phase 1 | Olema Pharmaceuticals, Inc. | <1 mi |
| National Cancer Institute "Cancer Moonshot Biobank" | — | National Cancer Institute (NCI) | <1 mi |
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | Phase 1/2 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | <1 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | <1 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | <1 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | <1 mi |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies | Phase 1/2 | ALX Oncology Inc. | <1 mi |
| ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions | N/A | ARTIDIS AG | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | <1 mi |
| Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Phase 2 | Vanderbilt-Ingram Cancer Center | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase 2 | Weill Medical College of Cornell University | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | <1 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | <1 mi |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | Persephone Biosciences | <1 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1/2 | LigaChem Biosciences, Inc. | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | Phase 4 | Guerbet | <1 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | <1 mi |
| QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | — | Abramson Cancer Center at Penn Medicine | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | — | M.D. Anderson Cancer Center | <1 mi |
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Phase 2 | Atossa Therapeutics, Inc. | <1 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | <1 mi |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Patient Priorities for Survivorship Care in Older Breast Cancer Survivors | Phase 2 | The University of Texas Health Science Center, Houston | <1 mi |
| Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) | Phase 1/2 | Michelle S Ludwig | <1 mi |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | Phase 1 | Atavistik Bio, Inc | <1 mi |
| Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications | — | M.D. Anderson Cancer Center | <1 mi |
| Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. | N/A | M.D. Anderson Cancer Center | <1 mi |
| Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast Tissue | — | M.D. Anderson Cancer Center | <1 mi |
| An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery | Phase 2/3 | M.D. Anderson Cancer Center | <1 mi |
| Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies | Early 1 | Presage Biosciences | <1 mi |
| Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Phase 1 | Duke Street Bio Ltd | <1 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | <1 mi |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) | N/A | Fibralign Corporation | <1 mi |
| Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | Phase 1/2 | M.D. Anderson Cancer Center | <1 mi |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Phase 1/2 | AtlasMedx, Incorporated | <1 mi |
| Magseed Enabled Long-Term Localization of Axillary Lymph Nodes | N/A | Endomagnetics Ltd. | <1 mi |
| TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd | Phase 2 | Ana C Garrido-Castro, MD | <1 mi |
| Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer | Phase 1 | OncoTherapy Science, Inc. | <1 mi |
| EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Phase 2 | Massachusetts General Hospital | <1 mi |
| Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE) | N/A | Breast Cancer Trials, Australia and New Zealand | <1 mi |
| Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics | N/A | M.D. Anderson Cancer Center | <1 mi |
| Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response | — | Sunnybrook Health Sciences Centre | <1 mi |
| Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | Phase 1/2 | Aminex Therapeutics, Inc. | <1 mi |
| A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | <1 mi |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | Olema Pharmaceuticals, Inc. | <1 mi |
| Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer | N/A | M.D. Anderson Cancer Center | <1 mi |
| Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | <1 mi |
| Improving Comprehensive Care of Cancer Patients | N/A | Baylor College of Medicine | <1 mi |
| Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | Phase 2 | Baylor Breast Care Center | <1 mi |
| Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery | N/A | M.D. Anderson Cancer Center | <1 mi |
| Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI) | N/A | M.D. Anderson Cancer Center | <1 mi |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | N/A | M.D. Anderson Cancer Center | <1 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | <1 mi |
| Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | Phase 2 | Laura Huppert, MD, BA | <1 mi |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) | — | University of California, San Francisco | <1 mi |
| Breast Mesh Used in Two-staged Breast Reconstruction | N/A | Tianjin Medical University Cancer Institute and Hospital | <1 mi |
| Study of 68Ga-R10602 | Phase 1 | Radionetics Oncology | <1 mi |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 2 | Bayer | <1 mi |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | Phase 1 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | <1 mi |
| The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts | N/A | M.D. Anderson Cancer Center | <1 mi |
| Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | <1 mi |
| A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment | N/A | M.D. Anderson Cancer Center | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT Study | — | M.D. Anderson Cancer Center | <1 mi |
| The PREDICT Registry: | — | PreludeDx | <1 mi |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Phase 1 | Edgewood Oncology Inc. | <1 mi |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | <1 mi |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | Phase 1 | Qurgen Inc. | <1 mi |
| Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Phase 1 | BeOne Medicines | <1 mi |
| TRUDI: TDXD+Durva in HER2+/Low IBC | Phase 2 | Filipa Lynce, MD | <1 mi |
| ETHAN - ET for Male BC | Phase 2 | Jose Pablo Leone | <1 mi |
| Multi-center MRD Registry for Inflammatory Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ | Phase 3 | Uppsala University | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Phase 1 | Avacta Life Sciences Ltd | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| An Ophthalmic Safety Study in Patients With Breast Cancer | — | AstraZeneca | <1 mi |
| Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen | — | M.D. Anderson Cancer Center | <1 mi |
| Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Phase 1/2 | Strand Therapeutics Inc. | <1 mi |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge | N/A | M.D. Anderson Cancer Center | <1 mi |
| Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | Phase 2 | The Methodist Hospital Research Institute | <1 mi |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk | — | M.D. Anderson Cancer Center | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | <1 mi |
| Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance Metrics | — | M.D. Anderson Cancer Center | <1 mi |
| BostonGene and Exigent Genomic INsight Study | — | BostonGene | <1 mi |
| Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | <1 mi |
| Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy | — | M.D. Anderson Cancer Center | <1 mi |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Phase 1/2 | AstraZeneca | <1 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | <1 mi |
| Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors | Phase 1 | Baylor College of Medicine | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | <1 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | <1 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | <1 mi |
| A Study of DM001 in Patients With Advanced Solid Tumors | Phase 1 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | <1 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | Mersana Therapeutics | <1 mi |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | Phase 1 | Fate Therapeutics | <1 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | <1 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | <1 mi |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| Comprehensive Outcomes for After Cancer Health | N/A | Pack Health | <1 mi |
| SMP-3124LP in Adults With Advanced Solid Tumors | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Phase 1/2 | Tanabe Pharma America, Inc. | <1 mi |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Phase 1 | M.D. Anderson Cancer Center | <1 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Tirzepatide Weight Loss for MRD+ Early Breast Cancer | Phase 2 | Baylor Research Institute | <1 mi |
| Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy | N/A | Deborah Farr, MD | <1 mi |
| GammaPod Registry and Quality of Life Nomogram | — | University of Maryland, Baltimore | <1 mi |
| A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Phase 1/2 | Gilead Sciences | <1 mi |
| Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | <1 mi |
| Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC | Early 1 | Baylor Research Institute | <1 mi |
| Susan G. Komen's ShareForCures | — | Susan G. Komen Breast Cancer Foundation | <1 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Phase 1 | Hefei TG ImmunoPharma Co., Ltd. | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort | Phase 2 | Sonya Reid | <1 mi |
| Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer | Phase 2/3 | Kibo Nam | <1 mi |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Phase 1/2 | Blue Earth Diagnostics | <1 mi |
| Neratinib in Combination With Ruxolitinib in Patients With mTNBC | Early 1 | Baylor Research Institute | <1 mi |
| Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial | Phase 2 | University of Texas Southwestern Medical Center | <1 mi |
| Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors | Phase 1 | Innate Pharma | <1 mi |
| JAB-2485 Activity in Adult Patients With Advanced Solid Tumors | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | <1 mi |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | BeiGene | <1 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 9 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 23 mi |
| Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai | — | Feminai | 26 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | 42 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 42 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | 42 mi |
| THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation | N/A | The University of Texas Medical Branch, Galveston | 47 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | 47 mi |
| Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery | N/A | Innoblative Designs, Inc. | 47 mi |